- Epizyme expected to hold IPO during week of May 27 May 24, 2013Epizyme Inc., a venture-backed biotech based in Cambridge, Mass., with ambitious plans for seeking drug approvals, is set to go public during the week of May 27, according to Renaissance Capital. The initial public offering of about 4.3 million shares, plus another 643,000 in over-allotments, could raise as much as $74 million at the top of the share price range, which is $15, according to a filing with the Securities and Exchange Commission. Epizyme plans to list on the Nasdaq market under the…
- NuoDB co-founder and CTO departs, succeeded by early employee May 24, 2013Cambridge-based NuoDB, developer of a database built to work in the cloud which aims to power the Web of the future, says co-founder Jim Starkey has retired from the CTO position at the firm. He has been succeeded in the role by company developer Seth Proctor. Starkey had spent three decades working in databases, starting at Digital Equipment Corp. and going on to found Interbase Software and Netfrastructure. Starkey co-founded NuoDB with CEO Barry Morris in 2010, and will remain involved with the…
- FINRA raps LPL with $7.5M fine May 24, 2013The Financial Industry Regulatory Authority has fined LPL Financial LLC $7.5 million for dozens of email failures and for making misstatements to regulators during a recent investigation. LPL’s email system seems to have been an afterthought during the firm’s rapid growth over the last five or six years, according to FINRA, Wall Street’s self-regulator. The firm’s failure to update its email systems made them “increasingly complex and unwieldy for LPL to manage and monitor effectively,”…
- Interleukin on track to commercialize periodontal disease test May 24, 2013It was a close call for Interleukin Genetics Inc. (OTCQB:ILIU), but the company said it is on track. The Waltham, Mass. diagnostics company received word that its University of Michigan study has been accepted for publication with just a week to go. The study, which showed the value of PST - a genetic test that measures the risk of developing periodontal disease - was the last piece the company needed to be able to move forward. The study showed the test guided better prevention of dental disease…
- Movers and Shakers: A look at who in bio is coming and going May 24, 2013The following personnel announcements at New England-area biotech companies have been made in recent weeks: Cambridge, Mass.-based Moderna Therapeutics announced the appointment of John Reynders as the company’s first chief information officer, effective in July. Reynders held several senior leadership positions at Johnson & Johnson, Lilly, and Celera Genomics including more recently serving as vice president of research and development information with AstraZeneca. In his newly-created role,…
- A revelation: Haverhill bible school has less-than-perfect grad rate (BBJ DataCenter) May 24, 2013It’s been roughly a week since we first published our list of the Massachusetts colleges with the best and worst graduation rates, and already we’ve seen a change atop the rankings. Sort of. After our story ran, we received word from Northpoint Bible College in Haverhill — the No. 1-ranked school on our list with a perfect 100 percent 4-year graduation rate — that its track record is something less than divine. It turns out the college miscalculated the grad rates it previously reported…
- Forget Restaurant Week: ArtWeek launches in Boston May 24, 2013With a concept like Boston’s popular Restaurant Week, Citi Performing Arts Center plans to launch ArtWeek Boston twice a year, starting in the fall, as a collection of arts, culture and entertainment events and experiences. Citi will work with venues in Boston and Cambridge. Some of the events will be for free. Other tickets will be sold at a fixed price – $20.13 and $40.13, according to Citi Performing Arts. “With ArtWeek, we can use the arts to strengthen our local economy,” said Josiah…
- Look to Dedham, ye laggard towns and cities! May 24, 2013Town Meeting season is in full swing in Massachusetts (rim shot, queue laugh track). Thank you, thank you. I’ll be here all week. But seriously folks, is there anything more ridiculous than a bunch of town officials making the case for new spending while at the same time ignoring the billions upon billions in unfunded health care IOUs they’ve collectively racked up over the years? Look, mama, there’s a pink elephant next to the moderator! Last I checked there were 165 Massachusetts towns…
- Aveo partner will not seek European approval for kidney cancer drug May 24, 2013Aveo Oncology (Nasdaq:AVEO) remained quiet Friday after the news that its partner to commercialize its potential drug for kidney cancer is giving up plans to seek approval for the drug in Europe, and won’t pay for further trials. Shares in Aveo opened Friday down 17 percent, but by noon, had risen to $2.58 a share, about 4 percent below Thursday’s close. Stock in the Cambridge, Mass.-based biotech is less than a third of the value it had prior to April 30. On that day, a posting on the U.S.…
- Hub’s condo market on fire May 24, 2013Boston’s scorching housing market set a first quarter record as the median price for a condominium reached the highest level of all time as inventory shrinks, according to the Listing Information Network, the Boston company that tracks sales. From January through March, 505 condos sold in the dozen downtown neighborhoods, an 8.3 percent increase from the same period last year and the highest first quarter volume since 2007 when 648 units sold. But rising prices are an even bigger story. The median…
Loading ...